354 related articles for article (PubMed ID: 33077920)
21. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
22. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal.
Prat J
Adv Anat Pathol; 1999 Sep; 6(5):247-74. PubMed ID: 10472378
[TBL] [Abstract][Full Text] [Related]
23. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
24. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
25. Miscellaneous types of surface epithelial neoplasms. The well-differentiated end of the morphologic spectrum of endometrioid, clear-cell, and Brenner tumors and mixed epithelioid tumors of low malignant potential of müllerian type.
Kempson RL; Hendrickson MR
Pathology (Phila); 1993; 1(2):335-65. PubMed ID: 9420923
[TBL] [Abstract][Full Text] [Related]
26. Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications.
Vemavarapu L; Alatassi H; Moghadamfalahi M
Int J Surg Pathol; 2011 Feb; 19(1):120-2. PubMed ID: 21087980
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
29. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
[TBL] [Abstract][Full Text] [Related]
30. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
31. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
32. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
Wang L; Allison D; Shukla PS
Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
34. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
35. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
[TBL] [Abstract][Full Text] [Related]
36. Borderline Brenner Tumor: A Review of the Literature.
Zheng R; Heller DS
Arch Pathol Lab Med; 2019 Oct; 143(10):1278-1280. PubMed ID: 30779594
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas.
Waldstrøm M; Grove A
Arch Pathol Lab Med; 2005 Jan; 129(1):85-8. PubMed ID: 15628914
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
39. Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison.
Austin RM; Norris HJ
Int J Gynecol Pathol; 1987; 6(1):29-39. PubMed ID: 3570630
[TBL] [Abstract][Full Text] [Related]
40. Ovarian Brenner tumors and transitional cell carcinoma: recent developments.
Roth LM; Gersell DJ; Ulbright TM
Int J Gynecol Pathol; 1993 Apr; 12(2):128-33. PubMed ID: 8463036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
